Oregovomab Combo Benefits Ovarian Cancers More Than Chemo Alone, Study Reports

Oregovomab Combo Benefits Ovarian Cancers More Than Chemo Alone, Study Reports
Adding oregovomab to standard chemotherapy significantly increases the time it takes for a newly diagnosed advanced ovarian cancer patient to have their disease progress or die, according to a Phase 3 clinical trial. OncoQuest, which developed oregovomab, will report the preliminary results of the trial at the American Society of Clinical Oncology meeting in Chicago next month.

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *